In particular, nuclear LSD1 phosphorylation at serine 111 (nLSD1p) is found to be enriched in both immunotherapy/chemoresistant-breast cancer cells with increased stem-like, mesenchymal signature [102]. Here, KDM1A is linked to breast cancer.